1099MO Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

1099MO Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 32; pp. S909 - S910
Main Authors: Hernando, J., Manzano, J.L., Teule, A., López, C., Garcia-Carbonero, R., Benavent Viñuales, M., Custodio, A., Cubillo, A., Alonso, V., Alonso-Gordoa, T., Carmona-Bayonas, A., Crespo, G., Blanco, M., Jimenez-Fonseca, P., Viudez, A., La Casta, A., Sevilla, I., Llanos, M., Segura, Á., Capdevila, J.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.181